Chemotherapy-Avastin Combination Boosts Progression Free Survival Time in Ovarian Cancer Patients


Advertisement
by Kathy Jones on  June 03, 2012 at 10:29 PM Cancer News
  •   Print
  •   Share
  •   Comments
  •  Text 
A new study has found that combining chemotherapy with Avastin could improve the progression-free period of patients with ovarian cancer.
 Chemotherapy-Avastin Combination Boosts Progression Free Survival Time in Ovarian Cancer Patients

Also known as bevacizumab and marketed as Avastin by the Swiss pharmaceutical giant Roche, the drug could help women who have a resistant form of the cancer, researchers said.

"For the first time in platinum resistant ovarian cancer, we have been able to significantly improve progression free survival with a combination therapy," said lead study author Eric Pujade-Lauraine, a professor at Universite de Paris Descartes.

"These results are very significant because the addition of bevacizumab offers a new treatment option for the 20 percent of women who have primary platinum resistant disease, as well as those whose disease later becomes platinum-resistant."

The international, randomized phase III clinical trial included 361 patients with ovarian cancer. Some received bevacizumab in addition to standard chemotherapies; others received chemo treatments alone.

The median time of progression free survival was 6.7 months in the combination therapy group, compared to 3.4 months in chemotherapy alone group.

Previous research has shown that bevacizumab can be effective as a first and second line treatment against ovarian cancer, and future studies may shed more light on when how long to administer it.

The latest research was presented at the annual conference of the American Society of Clinical Oncology in Chicago.

Some 230,000 women are diagnosed each year worldwide with ovarian cancer. About 70 percent of patients die within five years of diagnosis.

Source-AFP
Do you like this Report?
0

 Email Email  RSS Feeds RSS Feeds  Print this page Print  Save this page Save  Link Link  Syndicate Syndicate  Comments Comments 
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Related Links

Cancer Related News

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
Quiz on Cancer
Looking for information on cancer? Go through medindia's Cancer quiz.
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
Cancer
Complete Medindia Resources
News Categories:  
Senior Health Center